Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 2896, showing 100 per page
Biomarker NameUniProt IDPublicationConditionSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
CAST P20810 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CASP14 P31944 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CASKIN1 Q8WXD9 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CARTPT Q16568 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CARS1 P49589 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CARNS1 A5YM72 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CAPZB B1AK87 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CAPZA2 P47755 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CAPZA1 P52907 Zubiri et al. 2018 ALS fast – ALS slow (late stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CAPZA1 P52907 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast cohort) Plasma Down 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CAPZA1 P52907 Zubiri et al. 2018 Late ALS – Early ALS (ALS slow cohort) Plasma Down 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CAPZA1 P52907 Filareti et al. 2017 Late ALS – Early ALS PBMCs Down 4 Early-ALS, 4 Late-ALS 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
CAPS K7EL21 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CAPRIN1 A0A087X082 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CAPNS1 P04632 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CAPNS1 A0A0C4DGQ5 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CAPN5 A0A087X0C8 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CAPN1 P07384 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
CAPG P40121 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
CAPG P40121 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
CAP2 P40123 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CAP1 Q01518 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CAP1 Q01518 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CAP1 Q01518 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CANX P27824 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
CANX P27824 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CANX P27824 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CANX P27824 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
CAND1 Q86VP6 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CAMKV Q8NCB2 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CAMKK1 Q8N5S9 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CAMK2G Q13555 Umoh et al. 2018 ALS – Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
CAMK2B Q13554 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
CAMK2B Q13554 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CAMK2A Q9UQM7 Berrone et al. 2023 fALS – Control Plasma Up 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
CAMK2A Q9UQM7 Vu et al. 2023 ALS fast – ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CAMK2A Q9UQM7 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CAMK1D Q8IU85 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CALY Q9NYX4 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CALU O43852 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CALU O43852 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CALU O43852 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
CALR P27797 Berrone et al. 2023 fALS – Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
CALR P27797 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CALR P27797 Filareti et al. 2017 Late ALS – Early ALS PBMCs Up 4 Early-ALS, 4 Late-ALS 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
CALM1 P62158 Zubiri et al. 2018 ALS fast – ALS slow (late stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CALM1 P62158 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CALM1 P62158 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CALM1 P62158 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast cohort) Plasma Down 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CALM1 P0DP23 Englen-Lee et al. 2017 ALS – Control Spinal cord (PH & AH) Down 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6
CALM1 P0DP23 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
CALM1 P62158 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CALD1 Q05682 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
CALB2 P22676 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CALB2 P22676 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CADPS Q9ULU8 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CADM4 Q8NFZ8 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CADM4 Q8NFZ8 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CADM3 Q8N126 Collins et al. 2015 ALS – Control CSF Down 90 ALS, 80 control
CACNG8 Q8WXS5 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CACNA2D3 Q8IZS8 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CACNA2D1 P54289 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CACHD1 Q5VU97 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
CA2 P00918 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CA1 P00915 Berrone et al. 2023 ALS – Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
CA1 P00915 Berrone et al. 2023 fALS – Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
CA1 P00915 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CA1 P00915 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CA1 P00915 Bereman et al. 2018 ALS – Control Plasma Up 37 ALS, 30 control
C9 P02748 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
C9 P02748 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C9 P02748 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C9 P02748 Xu et al. 2018 ALS – Control Plasma Up 42 ALS, 18 control 61.8 ± 9.6
C9 P02748 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
C8G P07360 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C8B P07358 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C8B P07358 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
C8B F5GY80 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast cohort) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
C8B P07358 Bereman et al. 2018 ALS – Control CSF Up 33 ALS, 30 control
C8A P07357 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C8A P07357 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
C7 P10643 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C7 P10643 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
C7 P10643 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast and ALS slow cohort) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
C7 P10643 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast cohort) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
C7 P10643 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
C7 P10643 Katzeff et al. 2020 ALS – Control Serum Down 28 ALS, 22 control 52.7
C6 P13671 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
C6 P13671 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
C6 P13671 Berrone et al. 2023 fALS – Control Plasma Up 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
C6 P13671 Zhou et al. 2023 SO-ALS – Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
C6 P13671 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C6 P13671 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
C6 P13671 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
C6 P13671 Bereman et al. 2018 ALS – Control CSF Up 33 ALS, 30 control
C5 P01031 Berrone et al. 2023 fALS – Control Plasma Up 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
C5 P01031 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C5 P01031 Xu et al. 2018 ALS – Control Plasma Up 42 ALS, 18 control 61.8 ± 9.6
C5 P01031 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
C4BPB P20851 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)